SS-31 (Elamipretide): Mitochondrial Protection Peptide — Research Overview

SS-31 (Elamipretide): Mitochondrial Protection Peptide — Research Overview

> Research Disclaimer: This article is intended for laboratory and educational reference only. SS-31/Elamipretide is a research compound currently in clinical trials. All content is for scientific purposes only and does not constitute medical advice.

Introduction

SS-31, also known as Elamipretide or MTP-131, is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. It belongs to the Szeto-Schiller (SS) peptide family — a class of cell-permeable peptides designed to target the inner mitochondrial membrane.

Unlike most peptide research compounds, SS-31 has advanced into human clinical trials for multiple indications, making it one of the most clinically validated mitochondria-targeting peptides currently under investigation. Its primary mechanism — stabilizing cardiolipin on the inner mitochondrial membrane — addresses a fundamental aspect of mitochondrial dysfunction in aging and disease.

Molecular Structure

| Property | Value | |---|---| | Sequence | D-Arg-2'6'-Dmt-Lys-Phe-NH2 | | Molecular Weight | 639.8 g/mol | | CAS Number | 736992-21-5 | | Charge | +3 (cationic) | | Membrane Targeting | Inner mitochondrial membrane | | Cardiolipin Affinity | High (electrostatic + hydrophobic) |

The alternating aromatic and cationic residues in SS-31 are critical for its mitochondrial targeting. The cationic residues (D-Arg, Lys) are attracted to the highly negative mitochondrial membrane potential, while the aromatic residues (Dmt, Phe) interact with the acyl chains of cardiolipin.

Cardiolipin: The Key Target

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane (IMM). It plays essential structural and functional roles:

- Stabilizes the electron transport chain (ETC) complexes, particularly Complex I, III, IV, and V - Maintains the cristae architecture of the IMM - Facilitates cytochrome c binding and electron transfer - Regulates mitochondrial fusion/fission dynamics

In aging and disease states, cardiolipin undergoes peroxidation — oxidative damage to its four acyl chains — which destabilizes ETC complexes, reduces ATP production efficiency, and promotes cytochrome c release (triggering apoptosis). SS-31 binds to cardiolipin and prevents its peroxidation, thereby preserving ETC function and reducing reactive oxygen species (ROS) production.

Mechanism of Action

1. Cardiolipin Stabilization SS-31 binds cardiolipin on the IMM with high affinity, preventing peroxidation and maintaining the structural integrity of ETC supercomplexes. This is the primary mechanism underlying most of SS-31's observed effects.

2. ROS Reduction By stabilizing ETC complexes, SS-31 reduces electron leak at Complex I and III — the primary sites of superoxide generation. Studies consistently show 30-50% reductions in mitochondrial ROS production following SS-31 treatment in aged tissues.

3. ATP Production Enhancement Restoration of ETC complex activity and cristae architecture leads to improved mitochondrial membrane potential and increased ATP synthesis efficiency. This is particularly relevant in high-energy-demand tissues like cardiac and skeletal muscle.

4. Cytochrome c Retention SS-31 binding to cardiolipin reduces cytochrome c release from the IMM, thereby reducing apoptotic signaling in stressed cells.

Preclinical Research

Cardiac Aging and Heart Failure

SS-31 has been extensively studied in cardiac aging models. Research in aged mice demonstrated that SS-31 treatment restored cardiac mitochondrial function, improved cardiac output, and reversed age-related diastolic dysfunction [1]. Importantly, these improvements occurred within weeks of treatment, suggesting the effects are not dependent on new protein synthesis but rather on rapid restoration of existing mitochondrial architecture.

Skeletal Muscle Aging (Sarcopenia)

Studies in aged rodents showed SS-31 treatment improved skeletal muscle mitochondrial function, increased muscle fiber cross-sectional area, and improved exercise capacity [2]. The compound reversed age-related declines in mitochondrial cristae density and ETC complex activity.

Kidney Protection

Multiple studies have demonstrated SS-31's protective effects in models of acute kidney injury (ischemia-reperfusion, cisplatin nephrotoxicity), with significant reductions in tubular cell apoptosis and preservation of renal function.

Neurodegenerative Disease Models

SS-31 has shown protective effects in models of Alzheimer's disease, Parkinson's disease, and ALS, primarily through reduction of mitochondrial ROS and prevention of synaptic mitochondrial dysfunction.

Human Clinical Trials

SS-31/Elamipretide has advanced into Phase II and Phase III clinical trials, making it one of the most clinically advanced mitochondria-targeting peptides:

| Trial | Indication | Phase | Key Finding | |---|---|---|---| | PROGRESS-HF | Heart failure with preserved ejection fraction (HFpEF) | Phase II | Improved 6-minute walk distance; improved cardiac structure | | MMPOWER-3 | Barth syndrome (mitochondrial cardiomyopathy) | Phase III | Improved motor function; ongoing | | SPARCL | Limb-girdle muscular dystrophy | Phase II | Improved muscle function markers | | TAZPOWER | Barth syndrome | Phase II | Significant improvement in exercise capacity |

The TAZPOWER trial results, published in JACC: Heart Failure (2020), demonstrated that elamipretide significantly improved exercise capacity and quality of life in patients with Barth syndrome — a rare mitochondrial cardiomyopathy caused by cardiolipin deficiency [3].

Aging-Specific Research (2024-2026)

Recent research has focused specifically on SS-31's potential in the context of normal aging rather than disease:

- A 2024 study in aged non-human primates showed SS-31 treatment improved cardiac mitochondrial function and reduced markers of cellular senescence in cardiac tissue - Research in aged human skeletal muscle biopsies demonstrated that ex vivo SS-31 treatment restored mitochondrial respiration to levels comparable to young muscle tissue - A pilot human study in older adults with functional limitations showed trends toward improved physical performance metrics after 24 weeks of SS-31 treatment

Reconstitution Notes

SS-31 is typically supplied as a lyophilized powder and is water-soluble. Store at -20°C protected from light. Reconstitute in sterile saline or bacteriostatic water for research applications.

Conclusion

SS-31 (Elamipretide) represents one of the most mechanistically well-characterized and clinically advanced mitochondria-targeting peptides in current research. Its cardiolipin-binding mechanism addresses a fundamental aspect of mitochondrial aging — the progressive deterioration of IMM architecture and ETC function. With multiple Phase II/III trials demonstrating safety and efficacy in mitochondrial disease, SS-31 provides a validated research platform for studying mitochondrial dysfunction in aging and age-related conditions.

References

[1] Whitson JA, et al. "SS-31 and NMN: Two paths to improve metabolism and function in aged hearts." Aging Cell. 2020;19(1):e13065. https://pubmed.ncbi.nlm.nih.gov/31737983/

[2] Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-771. https://pubmed.ncbi.nlm.nih.gov/23692567/

[3] Thompson WR, et al. "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic cardiomyopathy." JACC Heart Fail. 2021;9(4):273-281. https://pubmed.ncbi.nlm.nih.gov/33549523/